Skip to main content
. 2004 May 17;101(21):8120–8125. doi: 10.1073/pnas.0401563101

Fig. 1.

Fig. 1.

Proliferating, and not resting, T cells are highly sensitive to bortezomib-mediated cytotoxicity. Allogeneic T cell responses are inhibited by bortezomib in vitro. (A–C) Proliferation and induction of apoptosis of alloreactive T cells in a MLR. (A) Alloreactive T cell proliferation was significantly decreased at days 3 and 5 (P < 0.001) in the presence of 2 nM (▾) and 4 nM (♦) but not 1 nM (▴) bortezomib. (B) Proportionally greater increase in annexin V binding on proliferating (CFSElo) compared with nonalloreactive (CFSEhi) CD4+ T cells with exposure to 4 nM bortezomib. (C) Proportionally greater increase in cell surface expression of annexin V on proliferating (CFSElo) compared with nonalloreactive (CFSEhi) CD8+ T cells with exposure to 2 and 4 nM bortezomib. *, significant differences of annexin V binding on bortezomib-exposed T cells compared with vehicle control (P < 0.05). The combined results of two independent experiments presented in B and C.